DBVT DBV Technologies S.A.
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1613780 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-31.5%
TTM net income YoY-65.6%
TTM EPS YoY42.3%
Revenue 3-yr CAGR-11.5%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-5,418.8%
Net margin-5,392.2%
FCF margin-4,986.9%
EBITDA margin—
Returns
ROE-205.8%
ROA-127.2%
ROIC (approx.)—
Asset turnover0.02x
Leverage & solvency
Liabilities / assets31.0%
Debt / equity0.00x
Current ratio3.24x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.91x
Accruals ratio-11.6%
Payout ratio—
Capex / revenue87.7%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $5.64M | $4.15M |
| R&D expense | $116.68M | $89.34M |
| SG&A expense | $32.79M | $28.74M |
| Operating income | -$147.06M | -$116.59M |
| Pretax income | -$146.46M | -$113.86M |
| Income tax | $491,000 | $55,000 |
| Net income | -$146.95M | -$113.92M |
| EBITDA | -$144.07M | -$113.87M |
| EPS (basic) | -1.05 | -1.17 |
| EPS (diluted) | -1.05 | -1.17 |
| Weighted avg. shares (diluted) | 139.57M | 97.00M |
| Balance sheet | ||
| Cash & equivalents | $194.20M | $32.50M |
| Current assets | $212.90M | $44.39M |
| PP&E, net | $10.40M | $11.31M |
| Intangibles | $0 | $40,000 |
| Total assets | $233.70M | $65.66M |
| Current liabilities | $58.00M | $31.14M |
| Long-term debt | $0 | — |
| Total debt | $0 | — |
| Total liabilities | $64.90M | $38.27M |
| Shareholders' equity | $168.80M | $27.40M |
| Net debt | -$194.20M | — |
| Shares outstanding | — | 102.85M |
| Cash flow statement | ||
| Operating cash flow | -$121.18M | -$104.47M |
| Capital expenditure | $532,000 | $2.34M |
| Free cash flow | -$121.71M | -$106.81M |
| Investing cash flow | -$1.37M | -$757,000 |
| Financing cash flow | $276.18M | $587,000 |
| Depreciation & amortization | $2.99M | $2.72M |
| Stock-based compensation | $5.39M | $4.62M |
Free plan shows the latest 2 periods; Pro shows all 11 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.